Suz Jack Chan

INTRODUCTION Current treatment paradigms for managing rheumatoid arthritis (RA) aim to prevent joint damage and disability by frequently assessing disease activity and altering disease-modifying antirheumatic drug (DMARD) therapy to achieve either remission or low disease activity (LDA).1 Since the introduction of biologic DMARDs (bDMARDs), more people with RA are able to achieve a state of LDA or remission.2 Although bDMARDs are effective, their high cost and adverse event profile have led...

Authors Yeo HY , Wong JHY, Chan SJ, Latu ATF, Han CH , Anwar M , Marra CA Received 11 October 2023 Accepted for publication 19 December 2023 Published 22 December 2023 Volume 2023:17 Pages 3525—3537 DOI https://doi.org/10.2147/PPA.S443217 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Johnny Chen Hui Yee Yeo,1,2 Jacqueline Hui Yi Wong,3 Suz Jack Chan,1 Anna Tiatia Fa’atoese Latu,1 Catherine H Han,4,5 Mudassir...